Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

<p>Clinical characteristics and their relationship with extending therapy after finishing 5-years adjuvant hormone therapy in women diagnosed with breast cancer in Stockholm, Sweden, 2005–2020.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Erwei Zeng (14958443) (author)
Autres auteurs:	Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author)
Publié:	2025
Sujets:	Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Survivorship Research Epidemiology of survivorship
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
par: Erwei Zeng (14958443)
Publié: (2025)

Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
par: Erwei Zeng (14958443)
Publié: (2025)

Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
par: Erwei Zeng (14958443)
Publié: (2025)

Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
par: Erwei Zeng (14958443)
Publié: (2025)

Figure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Figure 2 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Figure 3 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Figure 4 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Figure 5 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Table 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
par: Alba L. Combita (22677298)
Publié: (2025)

Image 1_Forgoing Healthcare and Insurance Premiums Trends: A 15-Year Population-Based Study in Geneva, Switzerland.png
par: Mayssam Nehme (10232172)
Publié: (2025)

Image 2_Forgoing Healthcare and Insurance Premiums Trends: A 15-Year Population-Based Study in Geneva, Switzerland.png
par: Mayssam Nehme (10232172)
Publié: (2025)

Supplementary file 1_Forgoing Healthcare and Insurance Premiums Trends: A 15-Year Population-Based Study in Geneva, Switzerland.docx
par: Mayssam Nehme (10232172)
Publié: (2025)

Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
par: Josephine K. Dermawan (17079555)
Publié: (2025)

Supplementary Tables S1-S12 from Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer
par: Achal Patel (5853731)
Publié: (2025)

Table S1 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S2 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S3 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S4 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S5 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S6 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S7 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
par: Karolin Heinze (16540724)
Publié: (2025)

Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
par: Karolin Heinze (16540724)
Publié: (2025)

Table 1 from Addressing Common Misuses and Pitfalls of <i>P</i> values in Biomedical Research
par: Ming Wang (8809334)
Publié: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
par: Shuwei Li (16437116)
Publié: (2025)

Characterization of a Novel Porcine Circovirus Type 2a Sequence and Anti-Viral Evaluation of Matrine and Sanguinarine Combined with Network Pharmacology and Molecular Docking
par: WENTING Qiao (22587494)
Publié: (2025)

Supplementary Table 19 from Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms
par: Pascal Belleau (14960153)
Publié: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
par: Sami Belhadj (15052341)
Publié: (2025)

Supplementary Table 1 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
par: Nneoma Adaku (16991063)
Publié: (2025)

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
par: Nneoma Adaku (16991063)
Publié: (2025)

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
par: Nneoma Adaku (16991063)
Publié: (2025)

Supplementary Data- Tables TS1-6 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
par: Rose B. McGee (15056564)
Publié: (2025)

Supplementary Data from Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics
par: Yuan Chun Ding (16721349)
Publié: (2025)

Table 1_Schistosomiasis and soil-transmitted helminthiasis prevalence and associated factors among school children in the Hawela Tula sub-city, Ethiopia: a cross-sectional study.docx
par: Addisalem Wube (22679048)
Publié: (2025)

Data Sheet 1_Schistosomiasis and soil-transmitted helminthiasis prevalence and associated factors among school children in the Hawela Tula sub-city, Ethiopia: a cross-sectional study.docx
par: Addisalem Wube (22679048)
Publié: (2025)

Planilha de dados
par: Vicente Neto (22677047)
Publié: (2025)

Supplementary Data from Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk
par: Fan Wang (14963418)
Publié: (2025)

Table S19 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
par: Zhenyuan Yu (14962287)
Publié: (2025)

Table S20 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
par: Zhenyuan Yu (14962287)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n4au7hbgrmjq0b19ru5ekg5a8f